Products
Brufen
Our nonsteroidal anti-inflammatory drug used to relieve pain, reduce inflammation and lower fever.
Oncology
Rising to cancer’s challenge
Cancer care in emerging markets faces challenges in access and affordability. Abbott is expanding access to biologic oncology treatments, helping more people receive life-changing therapies. Through strategic partnerships and local innovation, we’re committed to bringing advanced cancer care to more communities in emerging markets.
Women’s Health
Health at every stage of life
What makes Abbott a global leader in women’s health? We improve access to high-quality medicines for hard-to-treat diseases such as osteoporosis, breast cancer and menstrual disorders. We foster open dialogue about menopause, and we support women throughout their pregnancy. We also understand how cardiovascular disease and other conditions affect women differently. Everything we do shares a common purpose: supporting women’s health at every stage of their life and help them achieve their full potential.
Medication adherence
Better behaviors for better health
We all know that medicines only keep us healthy if we take them. But the reality is that around half of us don’t take our medicines as prescribed,1 and one-third never fill their prescriptions.2,3 Globally, this is a massive medical challenge that keeps people from living their healthiest lives.
A:CARE is our pioneering program developed with the brightest brains in behavioral science, which focuses on education, insights, and coaching to support healthcare professionals and help people better stick to their treatment so that they can live healthier lives.
A:CARE is our pioneering program developed with the brightest brains in behavioral science, which focuses on education, insights, and coaching to support healthcare professionals and help people better stick to their treatment so that they can live healthier lives.
Featured Medicines
Our medicines business aims to meet the health needs of countries where getting to see a doctor can be challenging. We are solely focused on emerging markets, and we have deep insight into the unique health challenges and needs of local communities in the world’s fastest-growing countries.
This information is intended for general awareness and does not replace professional medical advice. Please refer to local prescribing information.
Biosimilars: Improving global access
Biosimilars are transforming access to advanced treatments for serious conditions like cancer. At Abbott, we partner with leading biotech innovators to deliver high-quality biosimilars in emerging markets — making biologic therapies more affordable and accessible. Our commitment is to remove barriers to care and help more people live healthier lives.
The biosimilars story
Biosimilars are approved according to local regulatory standards and may not be interchangeable with reference products.
The biosimilars story
Biosimilars are approved according to local regulatory standards and may not be interchangeable with reference products.
Related articles
-
What are biologic medicines and biosimilars?
Abbott’s portfolio of biosimilars is making innovative biologic medicines more accessible. What’s the impact?
-
What are biosimilars, and how can they help you?
Five things to know about biosimilars and their potential to make life-saving treatments more accessible worldwide
-
Looking for more?
References
1Hichborn J, et al. Improving patient adherence through data-driven insights. McKinsey & Company. 2018. Available at: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/improving-patient-adherence-through-data-driven-insights
2Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-290.
3Organisation for Economic Co-operation and Development. OECD Health Working Paper No. 105 Investing in medication adherence improves health outcomes and health system efficiency – Adherence to medicines for diabetes, hypertension, and hyperlipidaemia. 2018. Available at: http://www.Oecd.Org/Officialdocuments/Publicdisplaydocumentpdf/?Cote=DELSA/HEA/WD/HWP(2018)2&Doclanguage=En>